Last reviewed · How we verify
Placebo to match OBV/PTV/r and DSV
This is an inert placebo formulation designed to match the appearance, taste, and administration characteristics of the active combination of ombitasvir/paritaprevir/ritonavir and dasabuvir.
This is an inert placebo formulation designed to match the appearance, taste, and administration characteristics of the active combination of ombitasvir/paritaprevir/ritonavir and dasabuvir. Used for Control arm in clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir for hepatitis C.
At a glance
| Generic name | Placebo to match OBV/PTV/r and DSV |
|---|---|
| Sponsor | Hannover Medical School |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Placebos are inactive substances used in clinical trials as control comparators to isolate the true therapeutic effect of an active drug. This particular placebo was manufactured to be indistinguishable from OBV/PTV/r and DSV (a hepatitis C antiviral regimen) in terms of physical properties and dosing schedule, ensuring blinding of trial participants and reducing bias in efficacy and safety assessments.
Approved indications
- Control arm in clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir for hepatitis C
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |